HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or company through licensing or co-development. HuniLife plans to enable these products to be tested in clinic as soon as the required preclinical development works are completed.
There are two major platform technologies for drug development at HuniLife, ENO1-targeting technology and Lactosome nanoparticle technology. HuL001 is a therapeutic antibody, based on the ENO1-targeting technology, and is designed for indications of autoimmune diseases and inflammatory disorder. HuL001 is expected to enter the Phase I by 2020. HuL002 is an oncology drug developed by utilizing Lactosome nanoparticle technology, which is designed to eliminate cancerous cells more efficaciously but with less toxicity and slated for entering preclinical development in 2020.
HuniLife R&D pipeline